Breaking News Instant updates and real-time market news.

NVS

Novartis

$88.85

0.68 (0.77%)

05:53
02/13/19
02/13
05:53
02/13/19
05:53

Clinigen buys U.S. rights to Novartis' cancer drug Proleukin

Clinigen Group has signed an agreement with Novartis to acquire the US rights to Proleukin or up to $210M in cash, consisting of an upfront and deferred payments along with future sales related milestones. Clinigen already owns the rights to Proleukin outside the US, which it acquired in July 2018. Total consideration includes: Initial $120M payable; $60M deferred consideration over the 12 months following completion; A further $30M consideration based on sales milestones. The completion of the acquisition is subject to US anti-trust clearance and is expected to occur in April 2019.

NVS Novartis
$88.85

0.68 (0.77%)

01/30/19
HCWC
01/30/19
NO CHANGE
Target $7
HCWC
Buy
Aduro Biotech strategic reset 'makes sense,' says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis said it "makes sense" for Aduro Biotech (ADRO) to reset its focus primarily on its two lead programs, STING and APRIL, and he believes a more focused strategy may further help "delineate clear clinical paths for these two assets." The analyst, who noted that Aduro is developing the STING pathway in oncology with partner Novartis (NVS), said he also believes the STING opportunity could be significant beyond oncology. He maintains a Buy rating on Aduro shares though he lowered his price target on the stock to $7 from $8.30 for the removal of the pLADD program from his projections and his adjustment of the base year.
01/30/19
HCWC
01/30/19
NO CHANGE
Target $281
HCWC
Buy
Amgen, Novartis reports show Ligand assets 'looking good,' says H.C. Wainwright
This morning, Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Promacta Q4 revenue of $330M, above H.C. Wainwright analyst Joseph Pantginis' estimate of $306M. Promacta has now hit its first year of blockbuster status with 2018 sales of $1.174B, which is an important feat in the face of new competition, Pantginis tells investors in a research note. The analyst believes Ligand's increasing royalty revenue streams and growing number of deals that result in milestones "effectively refute the bear thesis we've seen in a few other firms' freely accessible research." With Amgen (AMGN) reporting Q4 Kyprolis revenue of $251M, the analyst says Ligand's top assets are "looking good." He reiterates a Buy rating on the shares with a $281 price target.
01/30/19
WELS
01/30/19
NO CHANGE
WELS
Wells says Novartis report read-through 'neutral to negative' for Mylan, Teva
After Novartis' (NVS) Sandoz generics unit reported Q4 sales were down 2% in constant currency, due to a 7% decline in price and 5% increase in volume, Wells Fargo analyst David Maris noted that the majority of the price erosion came from the U.S. While the 2% decline was a sequential improvement from down 4% in Q3, Novartis was up against an easy comparison in the year ago period, Maris added. His view is that the U.S. generic market has not materially changed or improved at this point and he contends the report has a "neutral to negative read-through" relative to investors' expectations for Mylan (MYL) and Teva (TEVA).
02/06/19
BARD
02/06/19
INITIATION
Target $26
BARD
Cellular Biomedicine initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Cellular Biomedicine (CBMG) with an Outperform rating and a price target of $26. The analyst says the company's manufacturing capacity in cell therapy provide it with an edge in the "underappreciated China market", while its partnership with Novartis' (NVS) Kymriah in China validates its cell therapy manufacturing prowess. Given the multiple cell therapies expected in the next 12 months, Kumar says Cellular Biomedicine "could have a panoply of shots on goal over the coming year."

TODAY'S FREE FLY STORIES

AAOI

Applied Optoelectronics

$15.10

0.175 (1.17%)

11:10
02/20/19
02/20
11:10
02/20/19
11:10
Options
Applied Optoelectronics attracts a defensive option play ahead of earnings »

Applied Optoelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

11:10
02/20/19
02/20
11:10
02/20/19
11:10
General news
Oil Action: WTI crude »

Oil Action: WTI crude has…

CVS

CVS Health

$64.96

-4.96 (-7.09%)

, RAD

Rite Aid

$0.77

-0.0121 (-1.56%)

11:08
02/20/19
02/20
11:08
02/20/19
11:08
On The Fly
CVS plunges on weaker guidance after closing Aetna acquisition »

Shares of CVS Health…

CVS

CVS Health

$64.96

-4.96 (-7.09%)

RAD

Rite Aid

$0.77

-0.0121 (-1.56%)

CI

Cigna

$195.38

-2.8 (-1.41%)

UNH

UnitedHealth

$269.15

-1.11 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    May

MGLN

Magellan Health

$65.33

0.28 (0.43%)

11:05
02/20/19
02/20
11:05
02/20/19
11:05
Hot Stocks
Breaking Hot Stocks news story on Magellan Health »

Magellan Health jumps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

MGLN

Magellan Health

$65.33

0.28 (0.43%)

11:05
02/20/19
02/20
11:05
02/20/19
11:05
Periodicals
Breaking Periodicals news story on Magellan Health »

Magellan Health exploring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

WIX

Wix.com

$111.78

-13.92 (-11.07%)

11:05
02/20/19
02/20
11:05
02/20/19
11:05
Downgrade
Wix.com rating change  »

Rosenblatt downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 18

    Mar

TKC

Turkcell

$6.97

0.06 (0.87%)

11:02
02/20/19
02/20
11:02
02/20/19
11:02
Earnings
Turkcell reports FY net income 2.02B liras, consensus 1.93B liras »

Bloomberg reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 19

    Mar

VIA

Viacom

$34.98

0.13 (0.37%)

, VIAB

Viacom

$29.35

0.22 (0.76%)

11:02
02/20/19
02/20
11:02
02/20/19
11:02
Hot Stocks
Viacom, fuboTV announce distribution partnership »

Viacom and fuboTV…

VIA

Viacom

$34.98

0.13 (0.37%)

VIAB

Viacom

$29.35

0.22 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 27

    Feb

  • 04

    Mar

  • 11

    Mar

  • 11

    Mar

  • 11

    Mar

  • 11

    Mar

  • 06

    Jun

HRL

Hormel Foods

$42.86

-0.45 (-1.04%)

11:00
02/20/19
02/20
11:00
02/20/19
11:00
Options
Put buyers gobble up positions in Hormel Foods ahead of earnings »

Put buyers gobble up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

WIX

Wix.com

$112.09

-13.61 (-10.83%)

10:56
02/20/19
02/20
10:56
02/20/19
10:56
Downgrade
Wix.com rating change  »

Wix.com downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 18

    Mar

SJM

J.M. Smucker

$106.49

2.47 (2.37%)

10:54
02/20/19
02/20
10:54
02/20/19
10:54
Earnings
J.M. Smucker issues preliminary FY20 adjusted EPS growth outlook of 3%-4% »

In slides for its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 26

    Feb

SJM

J.M. Smucker

$106.08

2.06 (1.98%)

10:52
02/20/19
02/20
10:52
02/20/19
10:52
Hot Stocks
J.M. Smucker sees FY20 outlook helped by pet prices, hurt by peanut butter price »

In slides for its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 26

    Feb

ETM

Entercom

$7.73

0.22 (2.93%)

10:50
02/20/19
02/20
10:50
02/20/19
10:50
Options
Pre-earnings call buying in Entercom Communications »

Pre-earnings call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SJM

J.M. Smucker

$106.00

1.98 (1.90%)

10:48
02/20/19
02/20
10:48
02/20/19
10:48
Earnings
J.M. Smucker repeats FY19 adjusted EPS view of $8.00-$8.20, consensus $8.01 »

In slides for its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 26

    Feb

TGEN

Tecogen

$3.84

(0.00%)

10:48
02/20/19
02/20
10:48
02/20/19
10:48
Hot Stocks
Tecogen secures $8.4M trigeneration project in Manhattan »

Tecogen announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKC

Turkcell

$6.97

0.06 (0.87%)

10:47
02/20/19
02/20
10:47
02/20/19
10:47
Hot Stocks
Breaking Hot Stocks news story on Turkcell »

Turkcell trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 19

    Mar

HON

Honeywell

$153.66

0.39 (0.25%)

10:43
02/20/19
02/20
10:43
02/20/19
10:43
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell says UOP will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 29

    Apr

HON

Honeywell

$153.66

0.39 (0.25%)

10:41
02/20/19
02/20
10:41
02/20/19
10:41
Hot Stocks
Honeywell says UOP has been 'very disciplined' on the cost side »

Says Honeywell UOP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 29

    Apr

FITB

Fifth Third

$27.49

-0.025 (-0.09%)

10:40
02/20/19
02/20
10:40
02/20/19
10:40
Options
Bearish option flow in Fifth Third Bancorp »

Bearish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 12

    Mar

10:40
02/20/19
02/20
10:40
02/20/19
10:40
General news
Money market rates have dipped »

Money market rates have…

10:35
02/20/19
02/20
10:35
02/20/19
10:35
Conference/Events
Morgan Stanley sports/footwear analyst to hold analyst/industry conference call »

Sports & Footwear…

KO

Coca-Cola

$44.99

0.17 (0.38%)

10:30
02/20/19
02/20
10:30
02/20/19
10:30
Options
Vote of confidence in Coca Cola »

Vote of confidence in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

ARW

Arrow Electronics

$81.74

0.73 (0.90%)

10:28
02/20/19
02/20
10:28
02/20/19
10:28
Hot Stocks
Arrow Electronics CEO sells over $4.3M worth of shares »

Arrow Electronics CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

10:25
02/20/19
02/20
10:25
02/20/19
10:25
Conference/Events
Credit Suisse analysts to hold an analyst/industry conference call »

Analysts discuss the HOLT…

10:25
02/20/19
02/20
10:25
02/20/19
10:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.